- Home
- Publications
- Publication Search
- Publication Details
Title
Androgen Receptor in Breast Cancer: From Bench to Bedside
Authors
Keywords
-
Journal
Frontiers in Endocrinology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-09-02
DOI
10.3389/fendo.2020.00573
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prognostic Significance of Androgen Receptor Expression in Triple Negative Breast Cancer: A Systematic Review and Meta-Analysis
- (2020) Meng Xu et al. Clinical Breast Cancer
- The prognostic value of androgen receptor (AR) in HER2-enriched metastatic breast cancer
- (2020) Xinyue Wang et al. ENDOCRINE-RELATED CANCER
- Estrogen receptor beta increases sensitivity to enzalutamide in androgen receptor-positive triple-negative breast cancer
- (2019) Aristomenis Anestis et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Androgen receptor expression in circulating tumor cells of patients with metastatic breast cancer
- (2019) Ingeborg E. de Kruijff et al. INTERNATIONAL JOURNAL OF CANCER
- Androgen receptor: A promising therapeutic target in breast cancer
- (2019) Stella K. Vasiliou et al. CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES
- Estrogen Receptor Positive Breast Cancer with High Expression of Androgen Receptor has Less Cytolytic Activity and Worse Response to Neoadjuvant Chemotherapy but Better Survival
- (2019) Maiko Okano et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Consideration of breast cancer subtype in targeting the androgen receptor
- (2019) Clasina M. Venema et al. PHARMACOLOGY & THERAPEUTICS
- Androgen receptor in breast cancer: A wolf in sheep’s clothing? A lesson from prostate cancer.
- (2019) Samanta Salvi et al. SEMINARS IN CANCER BIOLOGY
- Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study
- (2019) Shristi Bhattarai et al. Cancers
- TBCRC 032 IB/II Multicenter Study: Molecular insights to AR antagonist and PI3K inhibitor efficacy in patients with AR+ metastatic triple-negative breast cancer
- (2019) Brian D. Lehmann et al. CLINICAL CANCER RESEARCH
- Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration‐resistant prostate cancer
- (2019) Xiaoliang Chen et al. PROSTATE
- Down-regulation of long non-coding RNA HOTAIR sensitizes breast cancer to trastuzumab
- (2019) Tianwen Chen et al. Scientific Reports
- Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?
- (2018) Giuseppe Bronte et al. BMC CANCER
- Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review
- (2018) Ricardo L. B. Costa et al. BREAST CANCER RESEARCH AND TREATMENT
- Inhibition of the Wnt/β-catenin pathway overcomes resistance to enzalutamide in castration-resistant prostate cancer
- (2018) Zhuangzhuang Zhang et al. CANCER RESEARCH
- Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
- (2018) L. Gerratana et al. CANCER TREATMENT REVIEWS
- An androgen receptor negatively induced long non-coding RNA ARNILA binding to miR-204 promotes the invasion and metastasis of triple-negative breast cancer
- (2018) Fang Yang et al. CELL DEATH AND DIFFERENTIATION
- The Application of Non-Invasive Apoptosis Detection Sensor (NIADS) on Histone Deacetylation Inhibitor (HDACi)-Induced Breast Cancer Cell Death
- (2018) Kai-Wen Hsu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer
- (2018) Tiffany A. Traina et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment-induced changes in the androgen receptor axis: Liquid biopsies as diagnostic/prognostic tools for prostate cancer
- (2018) S. Prekovic et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- NHERF1 Between Promises and Hopes: Overview on Cancer and Prospective Openings
- (2018) Matteo Centonze et al. Translational Oncology
- Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy
- (2018) Angela Santonja et al. Oncotarget
- Are There Differences in Androgen Receptor Expression in Invasive Breast Cancer in African (Tanzanian) Population in Comparison With the Caucasian (Italian) Population?
- (2018) Sara Bravaccini et al. Frontiers in Endocrinology
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- OUP accepted manuscript
- (2018) JNCI-Journal of the National Cancer Institute
- 368TiPSTART: A randomized phase II study in patients with triple negative, androgen receptor positive locally recurrent (unresectable) or metastatic breast cancer treated with darolutamide or capecitabine (UCBG-306)
- (2018) H Bonnefoi et al. ANNALS OF ONCOLOGY
- Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions
- (2018) Marcello Tucci et al. OncoTargets and Therapy
- Selective Androgen Receptor Modulator in a Patient With Hormone-Positive Metastatic Breast Cancer
- (2017) Namratha Vontela et al. Journal of the National Comprehensive Cancer Network
- Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer
- (2017) Michael A. Gordon et al. MOLECULAR CANCER THERAPEUTICS
- MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer Progression
- (2017) Jessica L. Christenson et al. Hormones & Cancer
- Androgen Receptor Function and Androgen Receptor–Targeted Therapies in Breast Cancer
- (2017) Miho Kono et al. JAMA Oncology
- AR Signaling in Breast Cancer
- (2017) Bilal Rahim et al. Cancers
- Expression and Clinical Significance of Androgen Receptor in Triple-Negative Breast Cancer
- (2017) Yuka Asano et al. Cancers
- Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells
- (2017) Chun-Yu Liu et al. PLoS One
- A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)
- (2016) H. Bonnefoi et al. ANNALS OF ONCOLOGY
- Impact of androgen receptor expression in fluoxymesterone-treated estrogen receptor-positive metastatic breast cancer refractory to contemporary hormonal therapy
- (2016) Miho Kono et al. BREAST CANCER RESEARCH AND TREATMENT
- Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis
- (2016) Mohammad A. Aleskandarany et al. BREAST CANCER RESEARCH AND TREATMENT
- Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer
- (2016) Erik Hilborn et al. BRITISH JOURNAL OF CANCER
- Antiproliferative Effect of Androgen Receptor Inhibition in Mesenchymal Stem-Like Triple-Negative Breast Cancer
- (2016) Aiyu Zhu et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data
- (2016) Ivana Bozovic-Spasojevic et al. CLINICAL CANCER RESEARCH
- Preclinical evaluation of the AR inhibitor enzalutamide in triple-negative breast cancer cells
- (2016) Francesco Caiazza et al. ENDOCRINE-RELATED CANCER
- Androgen and AR contribute to breast cancer development and metastasis: an insight of mechanisms
- (2016) J Feng et al. ONCOGENE
- A Targetable Androgen Receptor–Positive Breast Cancer Subtype Hidden Among the Triple-Negative Cancers
- (2015) Damoun Safarpour et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- ERβ1 inversely correlates with PTEN/PI3K/AKT pathway and predicts a favorable prognosis in triple-negative breast cancer
- (2015) Jin Wang et al. BREAST CANCER RESEARCH AND TREATMENT
- Combined Androgen and Estrogen Receptor Status in Breast Cancer: Treatment Prediction and Prognosis in a Population-Based Prospective Cohort
- (2015) K. Elebro et al. CLINICAL CANCER RESEARCH
- Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial
- (2015) Yohann Loriot et al. LANCET ONCOLOGY
- Multiple Molecular Subtypes of Triple-Negative Breast Cancer Critically Rely on Androgen Receptor and Respond to Enzalutamide In Vivo
- (2015) V. N. Barton et al. MOLECULAR CANCER THERAPEUTICS
- The history and future of targeting cyclin-dependent kinases in cancer therapy
- (2015) Uzma Asghar et al. NATURE REVIEWS DRUG DISCOVERY
- Targeting the Androgen Receptor in Breast Cancer
- (2015) KeeMing Chia et al. Current Oncology Reports
- Expression of androgen receptor splice variants in clinical breast cancers
- (2015) Theresa E. Hickey et al. Oncotarget
- PD-L1 is highly expressed in Enzalutamide resistant prostate cancer
- (2015) Jennifer L. Bishop et al. Oncotarget
- Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies
- (2015) Anu-Maarit Moilanen et al. Scientific Reports
- A Feedback Loop between Androgen Receptor and ERK Signaling in Estrogen Receptor-Negative Breast Cancer
- (2015) Kee Ming Chia et al. NEOPLASIA
- Cross-regulation between FOXA1 and ErbB2 Signaling in Estrogen Receptor-Negative Breast Cancer
- (2015) Ali Naderi et al. NEOPLASIA
- Androgen receptor: structure, role in prostate cancer and drug discovery
- (2014) MH Eileen Tan et al. ACTA PHARMACOLOGICA SINICA
- Complexities of androgen receptor signalling in breast cancer
- (2014) Keely M McNamara et al. ENDOCRINE-RELATED CANCER
- Anticancer Activity of a Novel Selective CYP17A1 Inhibitor in Preclinical Models of Castrate-Resistant Prostate Cancer
- (2014) P. J. Toren et al. MOLECULAR CANCER THERAPEUTICS
- Autophagy as a modulator and target in prostate cancer
- (2014) Jason M. Farrow et al. Nature Reviews Urology
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- (2014) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Selective androgen receptor modulators as improved androgen therapy for advanced breast cancer
- (2014) Christopher C. Coss et al. STEROIDS
- A simple and reproducible prognostic index in luminal ER-positive breast cancers
- (2013) I. Castellano et al. ANNALS OF ONCOLOGY
- Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes
- (2013) H. Masuda et al. CLINICAL CANCER RESEARCH
- Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer
- (2013) A. Gucalp et al. CLINICAL CANCER RESEARCH
- Androgen receptor expression is a predictive marker in chemotherapy-treated patients with endocrine receptor-positive primary breast cancers
- (2013) Isabell Witzel et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay
- (2013) Irène Baccelli et al. NATURE BIOTECHNOLOGY
- The G-protein-coupled estrogen receptor agonist G-1 suppresses proliferation of ovarian cancer cells by blocking tubulin polymerization
- (2013) C Wang et al. Cell Death & Disease
- An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)
- (2013) M. Korpal et al. Cancer Discovery
- Overcoming mutation-based resistance to antiandrogens with rational drug design
- (2013) Minna D Balbas et al. eLife
- Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network
- (2012) Nancy U. Lin et al. CANCER
- Androgen receptor (AR) aberrations in castration-resistant prostate cancer
- (2012) Kati K. Waltering et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Research Resource: Interplay between the Genomic and Transcriptional Networks of Androgen Receptor and Estrogen Receptor α in Luminal Breast Cancer Cells
- (2012) Eleanor F. Need et al. MOLECULAR ENDOCRINOLOGY
- Minireview: The Androgen Receptor in Breast Tissues: Growth Inhibitor, Tumor Suppressor, Oncogene?
- (2012) T. E. Hickey et al. MOLECULAR ENDOCRINOLOGY
- The mutational landscape of lethal castration-resistant prostate cancer
- (2012) Catherine S. Grasso et al. NATURE
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression
- (2012) Y Li et al. ONCOGENE
- Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy
- (2011) Sibylle Loibl et al. BREAST CANCER RESEARCH AND TREATMENT
- Targeting Androgen Receptor in Estrogen Receptor-Negative Breast Cancer
- (2011) Min Ni et al. CANCER CELL
- Common Structural and Epigenetic Changes in the Genome of Castration-Resistant Prostate Cancer
- (2011) T. W. Friedlander et al. CANCER RESEARCH
- Androgen Receptor Expression and Breast Cancer Survival in Postmenopausal Women
- (2011) R. Hu et al. CLINICAL CANCER RESEARCH
- Coordinated expression of oestrogen and androgen receptors in HER2-positive breast carcinomas: impact on proliferative activity
- (2011) Francini de Mattos Lima Lin et al. JOURNAL OF CLINICAL PATHOLOGY
- Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study
- (2011) Laura C Collins et al. MODERN PATHOLOGY
- Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers
- (2011) Y Wang et al. ONCOGENE
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
- (2010) Howard I Scher et al. LANCET
- Androgens in human breast carcinoma
- (2010) Takashi Suzuki et al. Medical Molecular Morphology
- Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor
- (2010) P. A. Watson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers
- (2010) Donata Micello et al. VIRCHOWS ARCHIV
- Expression of androgen receptors in primary breast cancer
- (2009) S. Park et al. ANNALS OF ONCOLOGY
- Combined androgen blockade with bicalutamide for advanced prostate cancer
- (2009) Hideyuki Akaza et al. CANCER
- Androgen Receptor Inhibits Estrogen Receptor- Activity and Is Prognostic in Breast Cancer
- (2009) A. A. Peters et al. CANCER RESEARCH
- Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer
- (2009) D. Sarker et al. CLINICAL CANCER RESEARCH
- Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation
- (2009) Leo A Niemeier et al. MODERN PATHOLOGY
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now